Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

(2010) J. Kikuchi et al.   BLOOD

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound  -phenylethyl isothiocyanate

(2010) Y. Hu et al.   BLOOD

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells

(2010) Feng Zhang et al.   CANCER BIOLOGY & THERAPY

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

(2010) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Phenethyl Isothiocyanate Inhibits Oxidative Phosphorylation to Trigger Reactive Oxygen Species-mediated Death of Human Prostate Cancer Cells

(2010) Dong Xiao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases

(2010) Shin-ichiro Imai et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Molecular Targets of Dietary Phenethyl Isothiocyanate and Sulforaphane for Cancer Chemoprevention

(2009) Ka Lung Cheung et al.   AAPS Journal

Camptothecin-Induced Cell Proliferation Inhibition and Apoptosis Enhanced by DNA Methyltransferase Inhibitor, 5-Aza-2′-deoxycytidine

(2009) Li Ding et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

(2009) C. P. Miller et al.   BLOOD

HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells

(2009) Xufeng Chen et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

(2009) S. Bhalla et al.   CLINICAL CANCER RESEARCH

Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes

(2009) Y. Huang et al.   CLINICAL CANCER RESEARCH

Modifying chromatin architecture during the response to DNA breakage

(2009) Ashok R. Venkitaraman   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Histone Deacetylase Inhibitors

(2009) Xujun Ma et al.   DRUGS

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Vorinostat in solid and hematologic malignancies

(2009) David Siegel et al.   Journal of Hematology & Oncology

A miniaturized screen for inhibitors of Jumonji histone demethylases

(2009) Masaaki Sakurai et al.   Molecular BioSystems

KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints

(2009) David N. Ciccone et al.   NATURE

Synergistic effect of trichostatin A and 5-aza-2′-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: A proteomic study

(2009) Daniela Cecconi et al.   PROTEOMICS

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

Oxidative Stress by Targeted Agents Promotes Cytotoxicity in Hematologic Malignancies

(2008) Joya Chandra   ANTIOXIDANTS & REDOX SIGNALING

Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B

(2008) David M. Gooden et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia

(2008) A. M. Roccaro et al.   BLOOD

Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism

(2008) D. Trachootham et al.   BLOOD

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

(2008) T. H. Luu et al.   CLINICAL CANCER RESEARCH

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

(2008) Susan C. Modesitt et al.   GYNECOLOGIC ONCOLOGY

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

(2008) Johan Vansteenkiste et al.   INVESTIGATIONAL NEW DRUGS

Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma

(2008) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

(2008) Roberto R. Rosato et al.   MOLECULAR CANCER THERAPEUTICS

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation

(2008) Jing Wang et al.   NATURE GENETICS

HDAC Inhibitors Act with 5-aza-2′-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells

(2008) Guolin Chai et al.   PLoS One

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

(2008) Elizabeth A. Griffiths et al.   SEMINARS IN HEMATOLOGY

Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells

(2007) Shan Gao et al.   LEUKEMIA RESEARCH